Rozlytrek Approved for Solid Tumors with NTRK Gene Fusion and for Metastatic ROS1-Positive NSCLC.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 22
- Publication type:
- Article
Works matching IS 21644403 AND DT 2019 AND VI 9 AND IP 9
Results: 9
1
2
FDA Approves Nubeqa for Nonmetastatic Castration-Resistant Prostate Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 22
- Publication type:
- Article
3
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 19
- By:
- Publication type:
- Article
4
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 16
- By:
- Publication type:
- Article
5
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 15
- By:
- Publication type:
- Article
6
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART "Basket" Clinical Trial.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 11
- By:
- Publication type:
- Article
7
Applying CAR T-Cell Therapies to Solid Tumors: Overcoming Current Challenges.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 1
- By:
- Publication type:
- Article
8
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion'Positive NSCLC.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 1
- By:
- Publication type:
- Article
9
National Oncology State Network: Making a Difference.
- Published in:
- Oncology Practice Management, 2019, v. 9, n. 9, p. 1
- By:
- Publication type:
- Article